Deutsche Bank AG Has $5.32 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Deutsche Bank AG lifted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 14.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 137,932 shares of the company's stock after acquiring an additional 17,763 shares during the quarter. Deutsche Bank AG owned about 0.23% of Protagonist Therapeutics worth $5,324,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Covestor Ltd boosted its stake in shares of Protagonist Therapeutics by 5,200.0% during the 4th quarter. Covestor Ltd now owns 1,643 shares of the company's stock worth $63,000 after acquiring an additional 1,612 shares in the last quarter. KBC Group NV boosted its stake in shares of Protagonist Therapeutics by 54.4% during the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after acquiring an additional 737 shares in the last quarter. New Vernon Capital Holdings II LLC bought a new stake in shares of Protagonist Therapeutics during the 4th quarter worth about $118,000. Nisa Investment Advisors LLC boosted its stake in shares of Protagonist Therapeutics by 10.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock worth $121,000 after acquiring an additional 295 shares in the last quarter. Finally, Cibc World Markets Corp bought a new stake in shares of Protagonist Therapeutics during the 4th quarter worth about $211,000. Institutional investors own 98.63% of the company's stock.

Insider Activity

In related news, CFO Asif Ali sold 24,903 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the completion of the sale, the chief financial officer now owns 62,821 shares in the company, valued at $3,689,477.33. This trade represents a 28.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director William D. Waddill sold 4,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the sale, the director now directly owns 13,130 shares in the company, valued at approximately $712,302.50. This represents a 23.35% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 61,173 shares of company stock worth $3,461,180. 4.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. BTIG Research set a $73.00 price target on Protagonist Therapeutics in a research note on Monday, March 3rd. Truist Financial increased their target price on Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a research note on Tuesday, March 11th. Wedbush reaffirmed an "outperform" rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a research report on Friday, March 28th. BMO Capital Markets increased their price objective on Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Finally, JMP Securities reiterated a "market outperform" rating and set a $58.00 target price on shares of Protagonist Therapeutics in a research note on Friday, February 7th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $65.44.

Protagonist Therapeutics Trading Down 0.5%

NASDAQ:PTGX traded down $0.25 during trading hours on Friday, hitting $45.66. 486,198 shares of the company traded hands, compared to its average volume of 881,795. Protagonist Therapeutics, Inc. has a twelve month low of $27.00 and a twelve month high of $60.60. The stock has a market capitalization of $2.83 billion, a price-to-earnings ratio of 17.17 and a beta of 2.65. The firm has a 50-day moving average of $45.86 and a 200 day moving average of $42.57.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.31. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The company had revenue of $28.32 million during the quarter, compared to analysts' expectations of $30.44 million. Equities research analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.